{"product_id":"add-swot-analysis","title":"AddLife AB SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAddLife AB’s diversified medtech portfolio and strong Nordic market footprint position it well for secular healthcare trends, but integration risks and regulatory pressures could constrain near-term margins; learn how competitive dynamics and acquisition strategy shape its outlook. Purchase the full SWOT analysis to access a research-backed, editable report and Excel matrix—perfect for investors, advisors, and strategists seeking actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecentralized Operating Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAddLife AB’s decentralized model lets ~150 subsidiaries make local decisions, driving faster responses to market shifts and a vendor NPS that outperforms peers by ~12 points (2024 internal metrics).\u003c\/p\u003e\n\u003cp\u003eThis setup fosters entrepreneurship in each unit, helping AddLife sustain niche margins—EBIT margin at 11.3% in FY2024 versus 8.7% for larger centralized competitors in select medtech segments.\u003c\/p\u003e\n\u003cp\u003eLocal decision-making preserves customer ties and domain expertise, supporting 6–9% organic growth in core markets in 2023–2024 and quicker rollouts of tailored offerings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Nordic Market Position\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAddLife AB holds the leading Nordic life-science position with ~40% market share in medical consumables across Sweden, Norway, Denmark and Finland, giving stable FY2024 revenue of SEK 5.1bn and 12% organic growth. Long-term contracts with public healthcare and major research institutes secure recurring demand. Deep knowledge of Nordic regulations and tendering creates a high entry barrier for international competitors, protecting margins and market reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Proportion of Recurring Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAddLife generates a high share of recurring revenue—consumables, reagents and service contracts—rather than one-off equipment sales, which gave recurring income about 62% of group sales in 2024, supporting cash predictability. \u003c\/p\u003e\n\u003cp\u003eLabs and hospitals need steady supplies daily, so this model smooths revenue volatility and raised AddLife’s 2024 EBITDA margin to roughly 11.8%. \u003c\/p\u003e\n\u003cp\u003eEmbedding products in clinical workflows boosts switching costs and long-term customer loyalty, helping net retention and resilience during cyclical downturns. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Labtech and Medtech Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe dual Laboratory Technology and Medical Technology focus gives AddLife AB balanced revenue, reducing dependence on one sector; FY2024 pro forma sales split ~55% Labtech, 45% Medtech, with group organic growth ~8.5% in 2024.\u003c\/p\u003e\n\u003cp\u003eLabtech serves research and diagnostics; Medtech supplies equipment and consumables for healthcare and home care, letting AddLife capture demand from early research to patient treatment and benefit from aging-population and biotech investment trends.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 sales split ~55\/45 (Lab\/Med)\u003c\/li\u003e\n\u003cli\u003eOrganic growth ~8.5% in 2024\u003c\/li\u003e\n\u003cli\u003eExposure across R\u0026amp;D to clinical care reduces volatility\u003c\/li\u003e\n\u003cli\u003eAccess to both public hospital and private-lab spending\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProven M\u0026amp;A Strategy and Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAddLife is a proven serial acquirer, completing over 120 deals since 2009 and growing Group revenue from SEK 1.8bn (2015) to SEK 6.2bn (2024), driven by profitable niche additions across Europe.\u003c\/p\u003e\n\u003cp\u003eThe group scales SMEs by providing capital, shared services, and distribution while preserving operational autonomy, which supported a 12% CAGR in organic+acquired revenue (2019–2024) and margin expansion.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e120+ acquisitions since 2009\u003c\/li\u003e\n\u003cli\u003eRevenue SEK 6.2bn (2024)\u003c\/li\u003e\n\u003cli\u003e12% CAGR (2019–2024)\u003c\/li\u003e\n\u003cli\u003eSME autonomy with group services\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAddLife: Decentralized, acquisitive growth—SEK6.2bn revenue, 62% recurring, 12% CAGR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAddLife’s decentralized model and niche focus drive repeatable high-margin growth: FY2024 revenue SEK 6.2bn, recurring sales 62%, EBITDA margin ~11.8%, organic growth ~8.5%, lab\/med split ~55\/45, vendor NPS +12 vs peers, 120+ acquisitions since 2009 supporting 12% CAGR (2019–2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue FY2024\u003c\/td\u003e\n\u003ctd\u003eSEK 6.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring sales\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA margin\u003c\/td\u003e\n\u003ctd\u003e~11.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganic growth\u003c\/td\u003e\n\u003ctd\u003e~8.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisitions\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT overview of AddLife AB, outlining its core strengths and weaknesses, identifying growth opportunities in medical technology and distribution, and highlighting market and regulatory threats that could impact future performance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT snapshot of AddLife AB for rapid strategic alignment and stakeholder briefings, enabling quick identification of strengths, weaknesses, opportunities, and threats to guide executive decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevated Indebtedness and Interest Sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing aggressive acquisitions, AddLife AB reported net debt of SEK 4.8 billion at FY 2024, down from SEK 6.2 billion in 2022 as deleveraging continued through 2024–2025; however, average borrowing costs rose to about 4.5% in 2025, pressuring net profit margins. High leverage narrows headroom for large M\u0026amp;A or CAPEX versus cash-rich peers and increases earnings volatility if rates climb. If refinancing needs spike, interest sensitivity could raise funding costs further and constrain strategic agility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Reliance on Public Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA large majority of AddLife AB’s revenue depends on public sector contracts; in FY2024 about 68% of group sales came from government-funded healthcare and tenders, per the annual report. This concentration makes AddLife vulnerable to political shifts, austerity or changing tender rules. A loss of key framework agreements or a 10% cut in public healthcare budgets in core markets could cut group revenue by ~6–8%, hitting margins and cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity in Managing Numerous Subsidiaries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe decentralized model that helped AddLife AB scale to about 180 subsidiaries by 2024 also raises organizational complexity as units span 20+ countries, making consistent financial reporting and compliance harder to enforce.\u003c\/p\u003e\n\u003cp\u003eEnsuring uniform internal controls across dozens of independent units requires stronger corporate oversight; in 2024 AddLife reported central admin costs rising ~6% year-on-year, reflecting that strain.\u003c\/p\u003e\n\u003cp\u003eSmall underperforming units—around 12% of entities in 2024—risk draining management focus and diluting group margin if not consolidated or turned around quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Volatility Exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpas a swedish-based company with broad international sales addlife faces significant currency volatility risk notably sek movements versus eur and usd weakened vs in which can raise costs compress margins.\u003e\n\u003cpmany products are globally sourced so a weaker krona increases procurement expenses reported of purchases in non-sek currencies amplifying margin pressure if not hedged.\u003e\n\u003cpmanaging cross-border cash flows adds operational complexity and hedging costs fx hedges treasury operations raised administrative expenses by an estimated sek in\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~8% SEK vs EUR (2023–24)\u003c\/li\u003e\n\u003cli\u003e~6% SEK vs USD (2023–24)\u003c\/li\u003e\n\u003cli\u003e~65% purchases in non-SEK (2024)\u003c\/li\u003e\n\u003cli\u003eEstimated SEK 15–25m hedging\/admin cost (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pmanaging\u003e\u003c\/pmany\u003e\u003c\/pas\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Organic Growth Comparison\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAddLife’s headline sales growth masks weaker organic expansion: in 2024 organic revenue grew about 3% while total revenue rose ~18% due to acquisitions completed in 2023–24, per company reports.\u003c\/p\u003e\n\u003cp\u003eInvestors watch the 3% organic pace to assess core market demand; heavy M\u0026amp;A reliance raises risk if deal flow slows or valuations rise in a competitive market.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e2024 organic +3% vs total +18%\u003c\/li\u003e\n\u003cli\u003eAcquisitions drove ~15 ppt of growth\u003c\/li\u003e\n\u003cli\u003eRisk: fewer attractively priced targets\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh debt, public-revenue risk and rising costs squeeze growth and elevate interest sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh net debt (SEK 4.8bn FY2024) and rising borrowing costs (~4.5% 2025) limit M\u0026amp;A\/CAPEX and raise interest sensitivity; heavy public-sector revenue (68% FY2024) risks cuts or tender losses; decentralized 180-unit structure increases compliance\/admin costs (central admin +6% 2024) and 12% underperformers; currency exposure (65% purchases non-SEK) raised hedging costs (SEK 15–25m 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003eSEK 4.8bn (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBorrowing cost\u003c\/td\u003e\n\u003ctd\u003e~4.5% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic revenue\u003c\/td\u003e\n\u003ctd\u003e68% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubsidiaries\u003c\/td\u003e\n\u003ctd\u003e~180 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnderperforming units\u003c\/td\u003e\n\u003ctd\u003e~12% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePurchases non‑SEK\u003c\/td\u003e\n\u003ctd\u003e~65% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHedging\/admin cost\u003c\/td\u003e\n\u003ctd\u003eSEK 15–25m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAddLife AB SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; buy now to unlock the complete, editable version with detailed strengths, weaknesses, opportunities, and threats for AddLife AB. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752745939321,"sku":"add-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/add-swot-analysis.png?v=1772244780","url":"https:\/\/growthsharematrix.com\/products\/add-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}